Advertisement

First Edition

October 12, 2018

  • Temporal auto-regulation during human PU.1 locus SubTAD formation
    Daniel Schuetzmann, Carolin Walter, Boet van Riel, Sabrina Kruse, Thorsten König, Tabea Erdmann, Alexander Tönges, Eric Bindels, Andre Weilemann, Claudia Gebhard, Klaus Wethmar, Chiara Perrod, Julia Minderjahn, Michael Rehli, Ruud Delwel, Georg Lenz, Stefan Gröschel, Martin Dugas and Frank Rosenbauer

October 11, 2018

October 10, 2018

October 09, 2018

  • Inflammatory signals directly instruct PU.1 in HSCs via TNF
    Martin Etzrodt, Nouraiz Ahmed, Philipp S. Hoppe, Dirk Loeffler, Stavroula Skylaki, Oliver Hilsenbeck, Konstantinos D. Kokkaliaris, Hans-Michael Kaltenbach, Jörg Stelling, Claus Nerlov and Timm Schroeder

October 04, 2018

  • Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
    Laurent Garderet, Frederique Kuhnowski, Benoit Berge, Murielle Roussel, Martine Escoffre-Barbe, Ingrid Lafon, Thierry Facon, Xavier Leleu, Lionel Karlin, Aurore Perrot, Philippe Moreau, Gerald Marit, Anne-Marie Stoppa, Bruno Royer, Carine Chaleteix, Mourad Tiab, Carla Araujo, Pascal Lenain, Margaret Macro, Eric Voog, Lofti Benboubker, Olivier Allangba, Eric Jourdan, Frederique Orcsini-Piocelle, Sabine Brechignac, Jean-Richard Eveillard, Karim Belhadj, Marc Wetterwald, Brigitte Pegourie, Arnaud Jaccard, Jean-Claude Eisenmann, Sylvie Glaisner, Mohamad Mohty, Cyrille Hulin, Herve Avet Loiseau, Claire Mathiot and Michel Attal
  • The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL
    Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia M. Kelly, Barry Turnbull and Stephan Stilgenbauer

October 03, 2018

  • TLT-1 is a Prognostic Indicator in ALI/ARDS and Prevents Tissue Damage in the Lungs in a Mouse model
    Jessica Morales-Ortíz, Victoria Deal, Fiorella Reyes, Gerónimo Maldonado-Martínez, Nahomy Ledesma, Franklin Staback, Cheyanne Croft, Amanda Pacheco, Humberto Ortiz-Zuazaga, C. Christian Yost, Jesse W. Rowley, Bismark Madera, Alex St. John, Junmei Chen, Jose Lopez, Matthew T. Rondina, Robert Hunter, Angela Gibson and A. Valance Washington
  • IG-MYC-positive neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas
    Rabea Wagener, Cristina López, Kortine Kleinheinz, Julia Bausinger, Sietse M. Aukema, Inga Nagel, Umut H. Toprak, Julian Seufert, Janine Altmüller, Holger Thiele, Christof Schneider, Julia Kolarova, Jeongbin Park, Daniel Hübschmann, Eva M. Murga Penas, Hans G. Drexler, Andishe Attarbaschi, Randi Hovland, Eigil Kjeldsen, Michael Kneba, Udo Kontny, Laurence de Leval, Peter Nürnberg, Ilske Oschlies, David Oscier, Brigitte Schlegelberger, Stephan Stilgenbauer, Wilhelm Wössmann, Matthias Schlesner, Birgit Burkhardt, Wolfram Klapper, Elaine S. Jaffe, Ralf Küppers and Reiner Siebert
  • FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia
    Jingliao Zhang, Yingchi Zhang, Man Zhang, Chao Liu, Xiaoming Liu, Jie Yin, Peng Wu, Xiaojuan Cheng, Wenyu Yang, Li Zhang, Ye Guo, Yao Zou, Yumei Chen, Youjia Cao, Tao Cheng and Xiaofan Zhu

October 02, 2018

October 01, 2018

September 28, 2018

September 27, 2018

September 26, 2018

September 25, 2018

  • A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
    Lisa S. Chen, Prithviraj Bose, Nichole D. Cruz, Yongying Jiang, Qi Wu, Philip A. Thompson, Shuju Feng, Michael H. Kroll, Wei Qiao, Xuelin Huang, Nitin Jain, William G. Wierda, Michael J. Keating and Varsha Gandhi
  • TET2 deficiency leads to stem cell factor dependent clonal expansion of dysfunctional erythroid progenitors
    Xiaoli Qu, Shijie Zhang, Shihui Wang, Yaomei Wang, Wei Li, Yumin Huang, Huizhi Zhao, Xiuyun Wu, Chao An, Xinhua Guo, John Hale, Jie Li, Christopher D. Hillyer, Narla Mohandas, Jing Liu, Karina Yazdanbakhsh, Francesca Vinchi, Lixiang Chen, Qiaozhen Kang and Xiuli An
  • T cell defects in patients with ARPC1B germline mutations account for their combined immunodeficiency
    Immacolata Brigida, Matteo Zoccolillo, Maria Pia Cicalese, Laurène Pfajfer, Federica Barzaghi, Serena Scala, Carmen Oleaga-Quintas, Jesus A. Álvarez-Álvarez, Lucia Sereni, Stefania Giannelli, Claudia Sartirana, Francesca Dionisio, Luca Pavesi, Marta Benavides-Nieto, Luca Basso-Ricci, Paola Capasso, Benedetta Mazzi, Jeremie Rosain, Nufar Marcus, Yu Nee Lee, Raz Somech, Massimo Degano, Giuseppe Raiola, Roberta Caorsi, Paolo Picco, Marcela Moncada Velez, Joelle Khourieh, Andrés Augusto Arias, Aziz Bousfiha, Thomas Issekutz, Andrew Issekutz, Bertrand Boisson, Kerry Dobbs, Anna Villa, Angelo Lombardo, Benedicte Neven, Despina Moshous, Jean-Laurent Casanova, José Luis Franco, Luigi D. Notarangelo, Cristina Scielzo, Stefano Volpi, Loïc Dupré, Jacinta Bustamante, Marco Gattorno and Alessandro Aiuti
  • Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
    Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie-Lorraine Chretien, Thomas Dejoie, Sabrina Maheo, Anne-Marie Stoppa, Brigitte Pegourie, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean-Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Brechignac, Brigitte Kolb, Cecile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Tom Willis, Malek Faham, Kenneth C. Anderson, Jean-Luc Harousseau, Xavier Leleu, Thierry Facon, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau and Nikhil Munshi
  • Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms
    James A. Kennedy, Jessie J. F. Medeiros, Stephanie M. Dobson, Andrea Arruda, Mahadeo A. Sukhai, Tracy Stockley, Anne Tierens, Mark D. Minden, Suzanne Kamel-Reid, John E. Dick and Vikas Gupta

September 24, 2018

  • SKI controls MDS-associated chronic TGFβ signaling, aberrant splicing, and stem cell fitness
    David E. Muench, Kyle Ferchen, Chinavenmeni S. Velu, Kith Pradhan, Kashish Chetal, Xiaoting Chen, Matthew T. Weirauch, Clemencia Colmenares, Amit Verma, Nathan Salomonis and H. Leighton Grimes
  • Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL
    Lorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, Maria Kemele, Natalie Fadle, Evi Regitz, Sarah Altmeyer, Claudia Schormann, Viola Poeschel, Marita Ziepert, Silke Walter, Patrick Roth, Michael Weller, Monika Szczepanowski, Wolfram Klapper, Camelia Monoranu, Andreas Rosenwald, Peter Möller, Sylvia Hartmann, Martin-Leo Hansmann, Andreas Mackensen, Henning Schäfer, Elisabeth Schorb, Gerald Illerhaus, Rolf Buslei, Rainer Maria Bohle, Stephan Stilgenbauer, Yoo-Jin Kim and Michael Pfreundschuh
  • Residual vein occlusion in relation to immediate compression and postthrombotic syndrome in deep vein thrombosis
    Elham E. Amin, Ingrid M. Bistervels, Karina Meijer, Lidwine W. Tick, Saskia Middeldorp, Guy Mostard, Marlène van de Poel, Erik H. Serné, Hans M. Otten, Edith M. Klappe, Manuela A. Joore, Hugo ten Cate, Marije ten Wolde and Arina J. Ten Cate-Hoek

September 21, 2018

September 20, 2018

September 19, 2018

  • Donor-derived MDS/AML in families with germline GATA2 mutation
    Pallavi Galera, Amy P. Hsu, Weixin Wang, Stephenie Droll, Rui Chen, Jason R. Schwartz, Jeffery M. Klco, Sally Arai, Luke Maese, Christa Zerbe, Mark J. Parta, Neal S. Young, Steven M. Holland, Dennis D. Hickstein and Katherine R. Calvo

September 18, 2018

September 13, 2018

September 12, 2018

September 11, 2018

Pages